New radioactive therapy targets tough childhood cancer
NCT ID NCT04023331
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a radioactive drug called 67Cu-SARTATE in 21 children with high-risk neuroblastoma that had relapsed or not responded to treatment. The drug is designed to deliver radiation directly to tumor cells. The goal was to find the safest dose and see if it shrinks tumors. The trial was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
67Cu-SARTATE (a radioactive drug that targets tumor cells)
What this could lead to
If successful, this could provide a new treatment option for children with hard-to-treat neuroblastoma that has come back or not responded to standard therapy.
What could go wrong
This is an early-phase trial with only 21 participants, so results may not apply broadly. The trial was terminated, which may indicate challenges. Radiation therapy can cause side effects like low blood counts or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Centre
Cincinnati, Ohio, 45229, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Phoenix Children's Hospital
Phoenix, Arizona, 85016, United States
-
University of Texas Southwestern Medical Centre
Dallas, Texas, 75390, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States